Testosterone Prevention Role in Men’s Health: Cardiovascular Dieseases

Background/objectives: Long-term testosterone therapy (TTh) in men with hypogonadism has been shown to improve all components of the metabolic syndrome.In this study, we investigated the effects of long-term TTh up to 8 years in hypogonadal men with a history of cardiovascular disease (CVD).Patients and methods: In two urological clinics observational registries, we identified 77 hypogonadal men receiving TTh who also had a history of CVD.The effects of TTh on anthropometric and metabolic parameters were investigated for a maximum duration of 8 years.Any occurrence of major adverse cardiovascular events was reported.All men received long-acting injections of testosterone undecanoate at 3-monthly intervals.Results: In 77 hypogonadal men with a history of CVD who received TTh, we observed a significant weight loss and a decrease in waist circumference and body mass index.Mean weight decreased from 11413 kg to 919 kg, change from baseline: -241 kg and -20.2%0.5%.Waist circumference decreased from 1128 cm to 996 cm, change from baseline: -130.3cm.Body mass index decreased from 374 to 293, change from baseline: -80.2 kg/m2.Cardiometabolic parameters such as lipid pattern, glycemic control, blood pressure, heart rate, and pulse pressure all improved significantly and sustainably.No patient suffered a major adverse cardiovascular event during the full observation time.Conclusion: In men with hypogonadism, TTh appears to be effective in achieving sustained improvements in all cardiometabolic risk factors and may be effective as an add-on measure in the secondary prevention of cardiovascular events in hypogonadal men with a history of CVD.